v2.4.0.8
Quarterly Statement of Operations Information - Summary of Quarterly Results of Operations (Detail) (USD $)
In Thousands, except Per Share data, unless otherwise specified
 3 Months Ended 12 Months Ended
Sep. 28, 2013
Jun. 29, 2013
Mar. 30, 2013
Dec. 29, 2012
Sep. 29, 2012
Jun. 23, 2012
Mar. 24, 2012
Dec. 24, 2011
Sep. 28, 2013
Sep. 29, 2012
Sep. 24, 2011
Quarterly Financial Information Disclosure [Abstract]                      
Total revenue $ 622,118 $ 626,136 $ 612,663 $ 631,362 $ 588,548 [1] $ 470,228 $ 471,165 $ 472,711 $ 2,492,279 $ 2,002,652 $ 1,789,349
Gross profit 290,631 309,758 279,326 281,673 274,317 [1] 244,640 226,110 249,370      
Net income (loss) $ (1,113,902) [2] $ (10,950) [2] $ (51,104) [2] $ 3,118 [2] $ (77,767) [1],[3] $ 23,594 [3] $ (40,273) [3] $ 20,812 [3] $ (1,172,838) $ (73,634) $ 157,150
Diluted net income (loss) per common share $ (4.11) $ (0.04) $ (0.19) $ 0.01 $ (0.29) [1] $ 0.09 $ (0.15) $ 0.08 $ (4.36) $ (0.28) $ 0.59
[1] The fourth quarter was a 14-week quarter compared to all other quarters which were 13-week quarters.
[2] Net income in the first quarter of fiscal 2013 includes a gain on the sale of intellectual property of $53.9 million. Net loss in the second quarter of fiscal 2013 includes restructuring charges of $12.5 million and a debt extingushment loss of $3.2 million. Net loss in the third quarter of fiscal 2013 includes restructuring charges of $6.7 million. Net loss in the fourth quarter of fiscal 2013 includes a goodwill impairment charge of $1.1 billion, restructuring charges of $9.7 million and a debt extinguishment loss of $6.0 million.
[3] Net loss in the second quarter of fiscal 2012 includes a charge for the discontinuance of the Adiana product line of $18.3 million and the loss on debt extinguishment of $42.3 million. See Note 5 for further discussion. Net loss in the fourth quarter of fiscal 2012 includes additional amortization expense from the Gen-Probe acquisition of $29.7 million, direct acquisition transaction costs of $30.7 million, and restructuring charges of $16.7 million, a goodwill impairment charge of $5.8 million and an in-process research and development charge of $4.5 million.